Elevated serum levels of both total and allergen-specific immunoglobulin E ( IgE ) correlate with atopic diseases such as allergic rhinitis and allergic asthma. Neutralization of IgE by anti-IgE antibodies can effectively treat allergic asthma.
Preclinical studies have indicated that targeting membrane IgE-positive cells with antibodies against M1 prime can inhibit the production of new IgE and significantly reduce the levels of serum IgE.
Researchers have reported results from two trials that investigated the safety, pharmacokinetics, and activity of Quilizumab, a humanized monoclonal antibody targeting specifically the M1 prime epitope of membrane IgE, in subjects with allergic rhinitis or mild allergic asthma.
In both studies, Quilizumab treatment was well tolerated and led to reductions in total and allergen-specific serum IgE that lasted for at least 6 months after the cessation of dosing.
In subjects with allergic asthma who were subjected to an allergen challenge, Quilizumab treatment blocked the generation of new IgE, reduced allergen-induced early and late asthmatic airway responses by 26 and 36%, respectively, and reduced allergen-induced increases in sputum eosinophils by approximately 50% compared with placebo.
These studies have indicated that targeting of membrane IgE–expressing cells with anti-M1 prime antibodies can prevent IgE production in humans. ( Xagena )
Gauvreau GM et al, Sci Transl Med 2014;6:243ra85